Nuvilex has been diluting for at least 2 years now.
For the year ended April 30, 2013, the valuation allowance increased $256,694. NOTE 10 - COMMON STOCK TRANSACTIONS During the year ended April 30, 2012, 500,000 shares of common stock were issued in exchange for $21,000 cash. .04/share
During the year ended April 30, 2012, 14,605,614 shares of common stock were issued for stock previously granted and recorded for compensation and services.
During the year ended April 30, 2012, 23,575,000 shares of common stock were issued to officers of the Company for compensation.Shares were valued using the closing stock price on the day of issuance for a total expense of $1,160,880. .049/share
During the year ended April 30, 2012, 8,550,000 shares of common stock were issued for various services. Shares were valued using the closing stock price on the day of issuance for a total expense of $409,400. .047/share
During the year ended April 30, 2012, 9,250,000 shares of common stock were issued in exchange for $600,000 in cash advances to the Company. .064/shareIn addition, another 1,650,000 shares were issued as incentive for providing the cash advances to the Company. These additional shares were value at $101,750 .061/share and charged to interest expense
During the year ended April 30, 2012, 1,025,000 shares of common stock were issued to settle various debts. The shares were valued using the closing stock price on the day of issuance for a total expense of $55,725. .054/share
During the year ended April 30, 2013, 8,771,429 shares of common stock were issued for various services. Shares were valued using the closing stock price on the day of issuance for a total expense of $331,000. .037/share
During the year ended April 30, 2013, 3,592,656 shares of common stock were issued to settle various debts. The shares were valued using the closing stock price on the day of issuance for a total expense of $143,596. .0399/share
During the year ended April 30, 2013, 13,326,668 shares of common stock were issued to officers of the Company for compensation. Shares were valued using the closing stock price on the day of issuance for a total expense of $653,696. .049/share
I also want to make this note from last years 10-K while im at it.
(1) On or about July 10, 2013, the Company accepted the resignation from Dr. Robert F. Ryan as the Company’s Chief Financial Officer. Effective as of the same date, to fill the vacancy created by Dr. Ryan's resignation, the Board of Directors appointed Patricia Gruden as the Company's Interim Chief Financial Officer.
